Rationale Patients with sarcoidosis exhibit heightened risk for thromboembolic events from chronic inflammation, comorbidities, and treatment-related toxicity, which is further elevated in those with co-existing type 2 diabetes mellitus (T2DM). Preclinical studies suggest glucagon-like peptide-1 (GLP-1) analogs, including glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and glucose-dependent insulinotropic polypeptide (GIP)/GLP-1 co-agonists, possess antithrombotic properties. However, their thromboembolic effects in sarcoidosis patients remains unclear. We aim to evaluate the impact of GLP-1 analogs on thromboembolic risks in patients with co-morbid sarcoidosis and T2DM. Methods We conducted a retrospective cohort using the TriNetX Analytics Network international database. Adults (≥18 years) diagnosed with both sarcoidosis and T2DM between April 2005 and September 2023 were included. Patients receiving GLP-1 analogs were compared to those on dipeptidyl peptidase-4 inhibitors (DPP-4i). Eligible patients had at least one prescription for the study medications within a year before their sarcoidosis diagnosis. The primary outcomes were arterial thromboembolic events (ATE), including myocardial infarction (MI) and ischemic stroke, and venous thromboembolic events (VTE), comprising pulmonary embolism (PE) and deep vein thrombosis (DVT). Secondary outcomes evaluated individual components of ATE and VTE. Safety outcomes included serious gastrointestinal adverse events, including gastroparesis, biliary disease, pancreatitis, and bowel obstruction. We performed propensity score matching, adjusting for demographics, body mass index (BMI), hemoglobin A1c (HbA1c), comorbidities, long term steroid use, and medication use for diabetes, sarcoidosis, and thromboembolic conditions. Patients were matched 1:1 using the TriNetX platform, with standardized mean differences <0.1 indicating balance. A Cox proportional hazards model was used to assess outcomes, with p-values <0.05 considered statistically significant. Results The study included 2,451 patients with both sarcoidosis and T2DM, with 821 patients in each matched group. Patients in the GLP-1 cohort were younger (57.2±10.9 vs. 61.7±12.0 years) with higher BMI (36.2±8.4 vs. 32.4±8.0 kg/m2) and HbA1c (7.9±1.9 vs. 7.7±1.7 %). After matching, covariates were balanced, including age (59.1±10.7 vs. 58.9±12.1 years) and hemoglobin A1c (7.7±1.7 vs. 7.8±1.8 %). The GLP-1 group maintained a slightly higher mean BMI (34.7±8.1 vs. 33.9±8.2 kg/m2), but the subgroups were otherwise well-matched. GLP-1 users had a lower risk of VTE (Hazard ratio (HR), 0.50 [95% CI: 0.26-0.97]; p=0.035), DVT (HR, 0.25 [95% CI: 0.09-0.66]; p=0.003), and MI (HR, 0.43 [95% CI: 0.20-0.93]; p=0.028) compared to DPP-4i users. No significant differences were observed in ATE, ischemic stroke, PE, or gastrointestinal adverse event risk. Conclusion GLP-1 analogs may reduce VTE and MI risks in patients with co-existing sarcoidosis and T2DM.